1. GlucoLight

    0 Comments Leave a Comment

    1-15 of 26 1 2 »
    1. Mentioned In 26 Articles

    2. Monitoring blood constituent levels in biological tissue

      Monitoring blood constituent levels in biological tissue
      In accordance with the invention, a low coherence interferometer is used to non-invasively monitor the concentration of glucose in blood by shining a light over a surface area of human or animal tissue, continuously scanning the light over a two dimensional area of the surface, collecting the reflected light from within the tissue and constructively interfering this reflected light with light reflected along a reference path to scan the tissue ...
      Read Full Article
    3. Flowometry in optical coherence tomography for analyte level estimation

      Flowometry in optical coherence tomography for analyte level estimation
      Optical coherence tomography (herein "OCT") based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood ...
      Read Full Article
    4. Method For Data Reduction And Calibration Of An OCT-BASED Physiological Monitor

      Method For Data Reduction And Calibration Of An OCT-BASED Physiological Monitor
      The present invention relates to a method and system for estimating blood analyte levels using a noninvasive optical coherence tomography (OCT) based physiological monitor. An algorithm correlates OCT-based estimated blood analyte data with actual blood analyte data determined by other methods, such as invasively. OCT-based data is fit to the obtained blood analyte measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood analyte levels ...
      Read Full Article
    5. Methods And Systems For Analyte Level Estimation In Optical Coherence Tomography (Wo 2009/111542)

      Optical coherence tomography (herein 'OCT') based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood ...
      Read Full Article
    6. OCT based method for diagnosis and therapy

      This invention relates to a method of diagnosing or treating a biological subject, such as a person or animal, comprising the steps of subjecting at least a microsample of the subject's tissue to a physiological perturbation and measuring the response of the microsample to the perturbation using optical coherence tomography (OCT). In an exemplary embodiment, the concentration of glucose in the microsample is perturbed, as by providing the subject ...
      Read Full Article
    7. Newton Photonics Wins a NSF SBIR Grant for OCT Glucose Monitor

      The National Science Foundation has awarded a nearly half-million dollar grant to startup Newton Photonics Inc. to create a non-invasive optical sensor capable of continuously monitoring a patient’s glucose levels. The NSF made the $480,000 Phase 2 Small Business Innovation Research (SBIR) award on Nov. 3, explained the Newton-based company’s co-founder Shmuel Halevi. The firm specializes in making biophotonic sensors. The NSF cash will fund the company ...
      Read Full Article
    8. Location, Location—Innovation: Companies in key U.S. regions continue to dominate medtech innovation, but the names on their patents often come with overseas addresses.

      ...mpanies such as Glucolight Corp. (Bethlehem, PA) also have strong technologies rooted in scientific research. Glucolight's optical coherence tomography provides a more sophisticated means of continuous and noninvasive bl...
      Read Full Article
    9. 1-15 of 26 1 2 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About GlucoLight

    GlucoLight

    GlucoLight Corporation.  It is believed that GlucoLight has gone out of business.   GlucoLight was focused on the development of non-invasive medical monitoring products using Optical Coherence Tomography (OCT).  The company’s first development effort is SENTRIS-100 , a hospital-based monitor that will make continuous, non-invasive measurement and monitoring of blood glucose a reality. In four years, GlucoLight has taken the SENTRIS-100 from an idea to a working prototype currently in clinical trials, with a pivotal FDA trial expected to begin in 2008.  GlucoLight’s experienced management team comes from a broad cross section of business disciplines, including operations, finance, device technology, product development, and marketing. The company is led by CEO Ray Krauss, a 25-year veteran of the medical device industry and former executive with Johnson & Johnson.  The company’s start-up was supported by Ben Franklin Technology Partners of Northeastern Pennsylvania and Life Sciences Greenhouse of Central Pennsylvania, both sponsored by the Commonwealth of Pennsylvania. The company has also been financed by Matignon Technologies, one of the largest European venture funds focusing on medical technology.  Upon completion of SENTRIS-100 development for the hospital market, GlucoLight will focus on accelerating its development of a consumer monitor. GlucoLight does not market to, or make its devices available to the consumer market at this time.